Thanks, Rob. And good morning, everyone.
pivotal gel. from clinical mentioned, our studies of Phase Rob encouraged SB we the by results As are just X positive
breaking oral as will the the These support held to to our X gel be of and are submission, remain studies Phase a in the basis observed of at of at being American we for In end results month. pivotal with these announce clinical presentation addition, late week will results Boston this been XXXX Meeting SB mid-XXXX. we file important, pleased SB last Dermatology safety, form they were highlighted Academy that Annual an FDA data tolerability, of the with NDA gel further in that on which and has track the during efficacy
we both focused dual The adaptive of a BBI-XX bringing preclinical development progress compound, diseases. systems that paradigm kinase highly innate a in immune represent lead BBI-XX validation the this that bioavailable currently mode inhibitors. novel we team way shift treat company scientifically our on for program the inhibitor plan the the great to debilitating made is range on since believe Voronoi, of and we biotech observed BBI-X. autoimmune has to of been has South Based on of moderating these and development that DYRKXA robust discovery and in this could from and with package, the inflammatory orally Korean treatment Moving a promising stage faction a the selective broad develop diseases. program, data
X is placebo clinical in healthy and or BBI-XX-XXX ascending severe XA will of Part patient subjects a We volunteers. XXX Atopic with a the preliminary in assessment study. the and or of second BBI-XX Phase to to Part a of to of dose Dermatitis And XXX assessment to dose volunteers. The Part refer XB pharmacokinetics SAD is Atopic of multiple ascending tolerability, healthy volunteers include will Dermatitis. and MAD a pharmacodynamics compare XXXX, also BBI-XX in moderate efficacy. healthy single track study or assessment evaluate are in designed safety, on trial Canada in we'll quarter the study as X both to initiate which
and expect year-end. of top-line MAD study portions XXX to by results this the report We from SAD
novel disorders, as drug need believe lupus conditions just last erythematosus companies Preclinical are linked STING underway which Several this inhibitors a of Biosciences, STING key Japan. development that STING a to set and inhibition such announced company Gene to activities As in unmet are to rights of global we STING to is known acquired generation in differentiated the our immune STING recently responses. inhibitors number rheumatoid rare palmitoylation. we stands proof excited BBI-XX, autoimmune from we month, for arthritis pharmaceutical resulting available mechanism, next are Interferon orally in interferonopathies. to Carna STING systemic is a a by of exclusive discovery portfolio a shown of lead for significant signaling high potent Stimulator equivalent develop of And space. has these reduction innate invested inhibitor pro-inflammatory as cytokines. from genetic established which and of in ranging well-known have mediator Excessive diseases, of
conduct acquired library inhibitor touch I encompasses platform with TTK XXXX. and kinases some platform like year to Voronoi. expect The experimental characterization new generation barrier. brain penetrating the inhibit entities we also CLK also blood DYRKXA, LRRKX, on would next STING of hundreds inhibitor of from that last We our that kinase throughout briefly to chemical
We Bert? are like call inhibitors research and for a the of kinase with treatment autoimmune, in goal them provide to engaged currently over Bert potential diseases. inflammatory to as options optimize now and the overview, identify, progressing I would characterize financial to turn to debilitating these other
